Skip to Content

Covexin 8

This page contains information on Covexin 8 for veterinary use.
The information provided typically includes the following:
  • Covexin 8 Indications
  • Warnings and cautions for Covexin 8
  • Direction and dosage information for Covexin 8

Covexin 8

This treatment applies to the following species:
Manufacturer: Intervet/Merck Animal Health

Clostridium Chauvoei-Septicum-Haemolyticum-Novyi-Tetani-Perfringens Types C & D Bacterin-Toxoid

For Animal Use Only

Covexin 8 Indications

For the vaccination of healthy cattle and sheep as an aid in the prevention of diseases caused by Clostridium chauvoei, C. septicum, C. novyi Type B, C. haemolyticum (known also as C. novyi Type D), C. tetani and C. perfringens Types C and D.

Immunity is also provided as an aid in the prevention of diseases caused by the beta and epsilon toxins of an additional organism, C. perfringens Type B. Although C. perfringens Type B is not a significant problem in North America (US), immunity is derived from a combination of Type C (beta) and Type D (epsilon) C. perfringens fractions.

ADMINISTRATION AND DOSAGE: Shake well. Using aseptic technique.

CATTLE DOSAGE: Inject 5 mL subcutaneously or intramuscularly, repeated in 6 weeks. Revaccinate annually with 5 mL prior to periods of extreme risk or parturition. For animals subject to re-exposure to C. novyi Types B or D (C. haemolyticum) repeat the dose every 5 to 6 months. For C. perfringens Types B, C and D, revaccinate two weeks prior to parturition, introduction to lush pastures or finishing programs. Calves vaccinated under 3 months of age should be revaccinated at weaning or 4 to 6 months of age.

SHEEP DOSAGE: Inject 5 mL subcutaneously followed by a 2 mL dose in 6 weeks. Revaccinate annually with 2 mL prior to periods of extreme risk or parturition. For animals subject to re-exposure to C. novyi Types B or D (C. haemolyticum) repeat the dose every 5 to 6 months. Vaccination should be scheduled so that pregnant ewes receive their second vaccination or annual booster 2 to 6 weeks before lambing commences in the flock. Lambs should be given their primary course beginning at 10 to 12 weeks of age.

PRECAUTION: This product has been tested under laboratory conditions and shown to meet all Federal standards for safety and efficacy. This level of performance may be affected by conditions of use such as stress, weather, nutrition, disease, parasitism, other treatments, individual idiosyncrasies or impaired immunological competency. These factors should be considered by the user when evaluating product performance or freedom from reactions. Local reactions may be observed following subcutaneous administration to cattle.

Covexin 8 Caution

Store at 35°-45°F (2°-7°C). Protect from freezing. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Anaphylactoid reactions may occur following use. Antidote: Epinephrine.

Manufactured by SCHERING-PLOUGH ANIMAL HEALTH LIMITED, UPPER HUTT, NEW ZEALAND

Distributed by INTERVET, INC., OMAHA, NE 68103 U.S.A.

U.S. Veterinary Permit No. 311

 

Code

 

50 mL
Cattle-10 doses.
Sheep-10 primary/25 booster doses.

067697

128664

250 mL
Cattle-50 doses.
Sheep-50 primary/125 booster doses.

067696

133705

NAC No.: 1047033.3

MERCK ANIMAL HEALTH
Intervet Inc.

2 GIRALDA FARMS, MADISON, NJ, 07940
Customer Service:   800-521-5767
Order Desk:   800-648-2118
Technical Service (Companion Animal):   800-224-5318
Technical Service (Livestock):   800-211-3573
Fax:   973-937-5557
Website:   www.merck-animal-health-usa.com
Every effort has been made to ensure the accuracy of the Covexin 8 information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2016 North American Compendiums. Updated: 2016-10-31

Hide